TP53 R249

CI-VAR-00003786Explore in graph →ClinVar 376015 CIViC 119 rs587782329

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
TP53 R249	Doxorubicin	Predictive	B	Supports Sensitivity Response	3	accepted	EID399 Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53. PMID 9569050 · Berns et al., 1998 · Open in CIViC	civic
Unmapped disease1unmapped disease
TP53 R249	(functional)	Functional	D	Supports Loss Of Function	4	submitted	EID7340 A library of P53 mutant vectors and wt control was packaged to lentivirus and infected into p53-null H1299 cells at a concentration yielding 1 integration per cell. Relative abundance of each transcri… (full text at CIViC) PMID 29979965 · Kotler et al., 2018 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376015	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Hereditary cancer-predisposing syndrome; Li-Fraumeni syndrome 1	germline	3	Feb 16, 2024	clinvar